About Ligand-gated cation channel ZACN
Ligand-gated cation channel ZACN (ZACN) is a protein
from Homo sapiens identified by UniProt accession
Q401N2, 412 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Ligand-gated cation channel ZACN |
| UniProt accession | Q401N2 |
| Gene | ZACN |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (9)
Diseases linked to this target (Open Targets).
- neurodevelopmental disorder with seizures and brain atrophy · score 0.12
- lymphocyte count · score 0.03
- COVID-19 · score 0.01
- IGA glomerulonephritis · score 0.01
- neoplasm · score 0.00
- breast cancer · score 0.00
- head and neck squamous cell carcinoma · score 0.00
- myelodysplastic syndrome · score 0.00
- transient neonatal diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q401N2-F1 | alphafold | PREDICTED | 77.53 | — |
Amino-acid sequence (412 residues)
MMALWSLLHL TFLGFSITLL LVHGQGFQGT AAIWPSLFNV NLSKKVQESI QIPNNGSAPL LVDVRVFVSN VFNVDILRYT MSSMLLLRLS WLDTRLAWNT SAHPRHAITL PWESLWTPRL TILEALWVDW RDQSPQARVD QDGHVKLNLA LATETNCNFE LLHFPRDHSN CSLSFYALSN TAMELEFQAH VVNEIVSVKR EYVVYDLKTQ VPPQQLVPCF QVTLRLKNTA LKSIIALLVP AEALLLADVC GGLLPLRAIE RIGYKVTLLL SYLVLHSSLV QALPSSSSCN PLLIYYFTIL LLLLFLSTIE TVLLAGLLAR GNLGAKSGPS PAPRGEQREH GNPGPHPAEE PSRGVKGSQR SWPETADRIF FLVYVVGVLC TQFVFAGIWM WAACKSDAAP GEAAPHGRRP RL
Explore Ligand-gated cation channel ZACN with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets